<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04196790</url>
  </required_header>
  <id_info>
    <org_study_id>LUCAAT ( 29BRC19. 0224)</org_study_id>
    <nct_id>NCT04196790</nct_id>
  </id_info>
  <brief_title>Development of a Model to Predict the Risk of Venous Thromboembolic Events in Patients With Metastatic Bronchopulmonary Cancer</brief_title>
  <acronym>LUCAAT</acronym>
  <official_title>Développement d'un modèle prédictif du Risque de Survenue d'évènements Thromboemboliques Veineux Chez Les Patients Atteints de Cancer Broncho-pulmonaire métastatique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Venous thrombo-embolism (VTE) is a frequent and serious complication of cancer. However,
      predictive tools for VTE in cancer patients is lacking.

      In patients with metastatic broncho-pulmonarycancer, biochemical characteristics might help
      to identify patients at high risk for VTE.

      The aim of this study is to derive a predictive score combining clinical and biochemical
      variable that predict VTE in metastatic broncho-pulmonary cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Venous thrombo-embolism (VTE) is a frequent and serious complication of cancer. However,
      predictive tools for VTE in cancer patients is lacking.

      In patients with metastatic broncho-pulmonarycancer, biochemical characteristics might help
      to identify patients at high risk for VTE, particularly in adenocarcinoma.

      The aim of this study is to derive a predictive score combining clinical and biochemical
      variable that predict VTE in metastatic broncho-pulmonary cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2019</start_date>
  <completion_date type="Anticipated">December 18, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 18, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>venous thromboembolism at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>objectively diagnosed VTE based on validated diagnostic tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>one year</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival without progression</measure>
    <time_frame>one year</time_frame>
    <description>survival without progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VTE at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>VTE at 6 months</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Metastatic Bronchopulmonary Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        500 metastatic cancer patients prospectively recruited in this prospective cohort.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  metastatic broncho-pulmonary cancer

          -  age ≥18 years

          -  who are eligible for chemotherapy

          -  non opposition obtained

        Exclusion Criteria:

          -  age &lt;18 years

          -  pregnancy, breast feeding

          -  VTE in the past 6 months or at the time of cancer diagnosis

          -  surgery in the past 3 months

          -  refusal to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francis COUTURAUD</last_name>
    <phone>02-98-34-78-26</phone>
    <email>francis.couturuad@chu-brest.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis COUTURAUD</last_name>
      <email>francis.couturaud@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH des Pays de Morlaix</name>
      <address>
        <city>Morlaix</city>
        <zip>29600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe ROGE</last_name>
      <email>croge@ch-morlaix.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHIC de QUIMPER</name>
      <address>
        <city>Quimper</city>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florence VERGNE</last_name>
      <email>florence.vergne@ch-cornouaille.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 8, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available beginning two year and ending five years following the publication</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

